Forschungsdatenbank PMU-SQQUID

Two Cases of Severe Tick-Borne Encephalitis in Rituximab-Treated Patients in Germany: Implications for Diagnosis and Prevention
Steininger, PA; Bobinger, T; Dietrich, W; Lee, DH; Knott, M; Bogdan, C; Korn, K; Lang, R
OPEN FORUM INFECT DI. 2017; 4(4):
Übersichtsarbeiten

Abstract/Keywords Web of Science Full Text

PMU-Autor/inn/en

Dietrich Wenke

Abstract

Rituximab (RTX) has become a standard therapy for certain B cell malignancies and autoimmune diseases. We report 2 RTX-treated patients who developed severe tick-borne encephalitis virus (TBEV) infection. The inability to generate new antibody responses renders RTX-treated patients susceptible to TBEV, impedes laboratory diagnosis, and necessitates preventive vaccination in endemic areas.

Find related publications in this database (Keywords)

B cell depletion
immunoglobulins
tick-borne encephalitis
vaccination